Thermo Fisher unveils AI, manufacturing and clinical trial expansions at BIO 2026

IndustryProduct / Tech
โดย Business Wire·Read original
Summary · why it matters

Thermo Fisher Scientific is showcasing new capabilities across manufacturing, clinical development and AI-enabled research at BIO International 2026. The company highlighted expanded sterile fill-finish and device assembly capacity, including an expanded collaboration with SHL Medical at its Ridgefield, New Jersey site, along with added oral solid dose manufacturing and significant additional biologics drug substance capacity in the U.S. and Switzerland. It is launching new GMP monoclonal antibody manufacturing in Plainville, Massachusetts in the second half of 2026 and has expanded its global Bioprocess Design Center network with new facilities in the U.S. and India. On the clinical side, Thermo Fisher expanded digital research capabilities through the acquisition of Clario Holdings, which has supported approximately 70% of FDA and EMA novel drug approvals over the past decade, and is rolling out AI-enabled analytics to improve trial efficiency. The company also announced strategic relationships with NVIDIA, OpenAI, TetraScience and BenchSci to enhance AI-enabled scientific workflows, and through its Accelerator Drug Development program it is helping emerging biotech firms integrate AI, laboratory technologies and development capabilities.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 2 stocks
Thermo Fisher Scientific Inc
TMO
▲ PositiveTechnologyrelevance

Thermo Fisher is showcasing AI-enabled research, new manufacturing capacity, and clinical trial expansions at BIO 2026, including AI partnerships with NVIDIA and OpenAI.

NVIDIA Corporation
NVDA
▲ PositiveDemandrelevance

Thermo Fisher announced strategic relationships with NVIDIA to enhance AI-enabled scientific workflows, indicating demand for NVIDIA's AI technology.

Theme Impact 4

Off-coverage companies 5

BenchSciPrivate± Mixed
relevance

Clario HoldingsPrivate± Mixed
relevance

OpenAIPrivate± Mixed
relevance

SHL MedicalPrivate± Mixed
relevance

TetraSciencePrivate± Mixed
relevance

Related news

BioMarin Reports Positive Phase 3 VOXZOGO Hypochondroplasia Data and Files sNDA

BioMarin Pharmaceutical reported positive Phase 3 CANOPY-HCH-3 results for VOXZOGO in children with hypochondroplasia and submitted a supplemental FDA application to expand the drug's use, while also adding Bristol Myers Squibb research leader Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee. The late-stage data cover an indication with no approved treatments, and the company said the combination of the results and the board appointment underscores its focus on deepening its rare disease franchise and scientific oversight. BioMarin's narrative projects $5.0 billion revenue and $1.3 billion earnings by 2029, requiring 14.0% yearly revenue growth and about a $1.2 billion earnings increase from $73.0 million today, with a $91.42 fair value cited, a 43% upside to its current price. More pessimistic analysts warn that heavy reliance on a few rare disease drugs and uncertainty around future indications could leave BioMarin short of pre-news expectations of about US$4.7 billion in revenue and roughly US$509.5 million in earnings by 2029.
BMRN ▲
Biotech & Genomic Medicine ▲
Simply Wall St·4hRead more →

ChemoMetec Posts Record DKK511 Million Revenue, Guides FY26/27 to DKK545-575 Million

ChemoMetec reported record revenue of DKK511 million for its Q4 2026 fiscal year, up 3% year over year and 7% at constant exchange rates, with EBITDA rising 9% to DKK281 million and the EBITDA margin expanding to 55% from 52.1%. Instrument revenue grew 13% on the strength of XM products including NC-203, whose revenue jumped to DKK68.1 million from DKK27.7 million a year earlier, while the life science business, representing 95% of group revenue, grew 6% to approximately DKK485 million. Consumables revenue fell 4% on the US federal government shutdown in fall 2025, US and Canada revenue slipped 6% in reported terms, and the animal semen, beer and milk business dropped 32% amid a continued market exit. The company repurchased 105,000 shares at year-end for about DKK39 million and roughly 206,600 shares, or 1.2% of share capital, as of the call date, and ended with a cash position of approximately DKK290 million and equity of approximately DKK725 million. For FY2026/27, ChemoMetec guided revenue to DKK545 million to DKK575 million, implying roughly 7% to 13% growth, EBITDA to DKK300 million to DKK330 million, and CapEx to approximately DKK120 million, with CEO Martin Behrens saying the outlook excludes any contribution from the Roche, Tecan and Hamilton collaborations and from delayed XM orders.
0DZ0.LSE
Biotech & Genomic Medicine
GuruFocus·11hRead more →
▲

NAVER D2SF Backs ImpriMed in $10 Million Series A2 Bridge Round

NAVER D2SF, NAVER's in-house corporate venture arm, has invested in Silicon Valley precision medicine company ImpriMed, joining ImpriMed's $10 million Series A2 bridge round. The round was led by LB Investment, with participation from new investors NAVER D2SF, Samsung Securities, and Alois Ventures, plus follow-on investments from existing investors BonAngels and Han River Partners; it follows ImpriMed's $23 million Series A in 2023. ImpriMed combines ex vivo analysis of patient-derived live cancer cells with genomic, immunophenotypic, and clinical data through its xCellSense platform, and is developing AI models trained on more than 3.5 million data points. The company is preparing to commercialize products for blood cancers and blood infection, targeting FDA clearance and CLIA certification by Q1 2027 for an initial U.S. launch, while in South Korea its multiple myeloma prognosis and therapy-response software has been designated an Innovative Medical Device by the Ministry of Food and Drug Safety. ImpriMed was co-founded by CEO Sungwon Lim and CTO Jamin Koo, and its human healthcare expansion is supported by veterinary precision oncology work covering more than 27,000 tests for canine and feline lymphoma, used by over 600 veterinary hospitals across the United States, Canada, the United Kingdom, France, and South Korea.
016360.KO035420.KO1060.HK309960.KOCTO
Biotech & Genomic Medicine ▲
PR Newswire·21hRead more →
© 2026 MarketDXNews